Perspective is everything
Keep the pharmacy landscape in view
Looking for clinical reports, industry trends, company news, or PBM insights? You’re in the right place. CarelonRx helps you keep your eyes on the pharmacy landscape, right here. For regular perspective, be sure to subscribe to our monthly newsletter.
CarelonRx formulary development
July 23, 2025
Explore the evidence-based formulary development process at CarelonRx and how our clinical-first P & T approach focuses on member outcomes.
Full article 
Druginsights update Q2 2025
July 17, 2025
The CarelonRx DrugInsights report is a quarterly summary of molecular entities, formulations, and indications approved by the FDA. Access the Q2 2025 update.
Full article 
Prep medicines before a storm
July 11, 2025
As you pack a disaster kit with food, water, and supplies, CarelonRx has tips on including medicines you and your family members take.
Full article 
What are specialty drugs?
July 09, 2025
Learn more from CarelonRx about what specialty drugs are, how they are used, and why they're important to members and plan sponsors.
Full article 
Care for serious mental illness
June 25, 2025
Read how medication plays an important role in treatment of serious mental illness and how connected pharmacy care can enhance outcomes.
Full article 
Navigating specialty pharmacy 3 ways
June 18, 2025
Want to better understand the specialty pharmacy landscape to help prepare for costs and create guidelines? CarelonRx pharmacists discuss core strategies.
Full article 
Prior authorization--burden or benefit?
June 17, 2025
Discover how CarelonRx has transformed the evidence-based Prior Authorization process into a benefit for plan members, while reducing wait time.
Full article 
Community-centered MS care
May 29, 2025
Learn how a patient of Paragon Healthcare, a Carelon company that operates under CarelonRx, receives infusion treatments and community-centered care.
Full article 
Drug and biologic pipeline Q2 2025
May 20, 2025
The CarelonRx Drug and Biologic Pipeline Update is published each quarter to keep you informed about upcoming FDA approvals. Download the Q2 2025 report.
Full article 